SVP & Chief Commercial Officer Mark E. Delaney sells 7,946 shares of DGX at $187.35; holdings drop to 7,530 shares (-51.3%)
Mark E. Delaney, SVP & Chief Commercial Officer at Quest Diagnostics, sold 7,946 shares at $187.35 for $1,488,683.10, reducing his post-transaction holdings from 15,476 shares to 7,530 shares—a 51.3% reduction in his position. The sale occurred near the 52-week high of $190.58, with the current stock price at $187.61 and the company reporting strong fundamentals including $2.8B quarterly revenue, $245M net income, and 6.7% annual revenue growth. The magnitude of this sale—eliminating half his holdings—is notable for a senior commercial officer, though the transaction price proximity to recent highs provides context for the execution.